open access

Vol 56, No 2 (2005)
Original papers
Published online: 2006-03-24
Submitted: 2013-02-15
Get Citation

Influence of hormonal therapy on growth rate and bone age progression in patients with Turner syndrome

Aneta Gawlik, Tomasz Gawlik, Brygida Koehler, Ewa Małecka-Tendera, Maria Augustyn, William Woska
Endokrynologia Polska 2005;56(2):136-144.

open access

Vol 56, No 2 (2005)
Original papers
Published online: 2006-03-24
Submitted: 2013-02-15

Abstract

The efficacy of growth promoting hormonal therapy is assessed on the basis of growth rate as well as bone age progression until the patients reach their final height. The aim of our study was to investigate which hormonal therapy influences in most appropriate way height velocity and bone age progression in patients with Turner syndrome (TS) and to establish the optimal age to initiate treatment. Patients were divided into five groups according to the type of hormonal therapy:1) 11 patients treated with growth hormone (GH); 2) 18 patients treated with GH and oxandrolone (Ox); 3) 7 patients treated with GH, Ox and estrogens (E); 4) 6 patients treated with OX and E; and the control group (Group 0) of 62 untreated patients. The patients height was expressed in hSDS calculated on the basis of growth chart for patients with TS (hSDST). Bone age (BA) was assessed according to Greulich-Pyle method. Results: The mean values of ∆hSDST in the first and second year of therapy in individual groups were significantly different. The difference resulted from significantly higher value of ∆hSDST in group treated with GH+Ox. Analysis of regression between ∆CA and ∆BA revealed regression coefficients α of equation ∆BA= α x ∆CA: in group 0: 0.817; group GH: 1.233; group GH+Ox: 0.861; group GH+Ox+E: 0.997; group Ox+E: 1.141. There was significant difference between regression coefficients in studied groups. It resulted from significantly higher value of α in group treated with GH than in a group 0 and treated with GH+Ox. Only group treated with GH+Ox showed a significant negative correlation between baseline CA and ∆BA during the therapy. We can conclude that all regimens of hormonal therapy improved height in our patients but the highest increase of height during the therapy and the smallest progression of the bone age in the same time were observed in patients treated with GH+Ox.

Abstract

The efficacy of growth promoting hormonal therapy is assessed on the basis of growth rate as well as bone age progression until the patients reach their final height. The aim of our study was to investigate which hormonal therapy influences in most appropriate way height velocity and bone age progression in patients with Turner syndrome (TS) and to establish the optimal age to initiate treatment. Patients were divided into five groups according to the type of hormonal therapy:1) 11 patients treated with growth hormone (GH); 2) 18 patients treated with GH and oxandrolone (Ox); 3) 7 patients treated with GH, Ox and estrogens (E); 4) 6 patients treated with OX and E; and the control group (Group 0) of 62 untreated patients. The patients height was expressed in hSDS calculated on the basis of growth chart for patients with TS (hSDST). Bone age (BA) was assessed according to Greulich-Pyle method. Results: The mean values of ∆hSDST in the first and second year of therapy in individual groups were significantly different. The difference resulted from significantly higher value of ∆hSDST in group treated with GH+Ox. Analysis of regression between ∆CA and ∆BA revealed regression coefficients α of equation ∆BA= α x ∆CA: in group 0: 0.817; group GH: 1.233; group GH+Ox: 0.861; group GH+Ox+E: 0.997; group Ox+E: 1.141. There was significant difference between regression coefficients in studied groups. It resulted from significantly higher value of α in group treated with GH than in a group 0 and treated with GH+Ox. Only group treated with GH+Ox showed a significant negative correlation between baseline CA and ∆BA during the therapy. We can conclude that all regimens of hormonal therapy improved height in our patients but the highest increase of height during the therapy and the smallest progression of the bone age in the same time were observed in patients treated with GH+Ox.
Get Citation

Keywords

Turner syndrome; hormonal therapy; growth rate; bone age

About this article
Title

Influence of hormonal therapy on growth rate and bone age progression in patients with Turner syndrome

Journal

Endokrynologia Polska

Issue

Vol 56, No 2 (2005)

Pages

136-144

Published online

2006-03-24

Bibliographic record

Endokrynologia Polska 2005;56(2):136-144.

Keywords

Turner syndrome
hormonal therapy
growth rate
bone age

Authors

Aneta Gawlik
Tomasz Gawlik
Brygida Koehler
Ewa Małecka-Tendera
Maria Augustyn
William Woska

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl